Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Inclusion criteria : * Adult participants with a physician diagnosis of asthma for at least 12 months based on the Global Initiative for Asthma (GINA) 2017 Guidelines. * Participants with existing treatment with medium to high dose ICS (greater than or equal to \[\>=\] 250 microgram (mcg) of fluticasone propionate twice a day (BID) or equipotent ICS daily dosage to a maximum of 2000 mcg/day of fluticasone propionate or clinically comparable) in combination with a LABA as second controller for at least 3 months with a stable dose \>=1 month prior to Visit 1. * Participants with pre-bronchodilator FEV1 greater than (\>) 40 percent (%) of predicted normal at Visit 1/Screening. Pre-bronchodilator FEV1 \>=50% but less than or equal to (\<=) 85% of predicted normal at Visit 2/Baseline. * Participants with reversibility of at least 12% and 200 milliliters (mL) in FEV1 after administration of 2 to 4 puffs (200-400 microgram \[µg\]) of albuterol/salbutamol or levalbuterol/levosalbutamol during screening or documented history of a reversibility test that meets this criteria within 12 months prior to Visit 1 or documented positive response to methacholine challenge (a decrease in FEV by 20% \[PC20\] of less than \[\<\] 8 milligram per milliliter \[mg/mL\]) within 12 months prior to Visit 1/Screening is considered acceptable to meet this inclusion criterion. * Participants had experienced, within 1 year prior to Visit 1, any of the following events at least once: * Treatment with a systemic steroid (oral or parenteral) for worsening asthma. * Hospitalization or emergency medical care visit for worsening asthma. * Signed written informed consent. Exclusion criteria: * Participants \<18 years or \>70 years of age (i.e., have reached the age of 71 at the screening visit). * Participants with body mass index (BMI) \<16. * Chronic lung disease (for example, chronic obstructive pulmonary disease \[COPD\], or idiopathic pulmonary fibrosis \[IPF\]), which might impair lung function. * History of life threatening asthma (i.e., severe exacerbation that required intubation). * Co-morbid disease that might interfere with the evaluation of investigational medicinal product (IMP). * Participants with any of the following events within the 4 weeks prior to their Screening Visit 1: * Treatment with 1 or more systemic (oral and/or parenteral) steroid bursts for worsening asthma; * Hospitalization or emergency medical care visit for worsening asthma. * Asthma Control Questionnaire 5-question version (ACQ-5) score \<1.25 or \>3.0 at Visit 2/randomization. During the screening period, an ACQ-5 of up to \<=4 was acceptable. * Anti-immunoglobulin E (IgE) therapy (e.g., omalizumab \[Xolair®\]) within 130 days prior to Visit 1 or any other biologic therapy (including anti interleukin-5 \[anti-IL5\] monoclonal antibodies \[mAb\]) or systemic immunosuppressant (e.g., methotrexate) to treat inflammatory disease or autoimmune disease (e.g., rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) and other diseases, within 2 months or 5 half-lives prior to Visit 1, whichever was longer. * Participants with a history of a systemic hypersensitivity reaction to a biologic drug. * Participants on or initiation of bronchial thermoplasty within 2 years prior to Visit 1 or plan to begin therapy during the screening period or the randomized treatment period. * Current smoker or cessation of smoking within the 6 months prior to Visit 1. * Previous smoker with a smoking history \>10 pack-years. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.